Cipla reported INR44.1B in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Arca Biopharma 0 0 Mar/2025
aTyr Pharma USD 987.07K 797.07K Mar/2026
Capricor Therapeutics 11.13M 8.87M Dec/2024
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cipla INR 44.1B 5B Jun/2026
Dr.Reddys Laboratories INR 41.78B 4.02B Jun/2026
Immunic 0 0 Mar/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sun Pharmaceuticals INR 117.59B 7.65B Mar/2026
TherapeuticsMD USD 234K 79K Jun/2024
UPL INR 82.12B 26.16B Mar/2026